Phesgo and Tecentriq Performance and Approvals
Roche Group development pipeline
Phase III (9 NMES + 40 Als)
RG3502
RG6026
Kadcyla + T
HER-2+ eBC high-risk
RG3648
Xolair
Columvi (glofitamab) + chemo
tiragolumab + T
tiragolumab + T
RG6058
tiragolumab +T
tiragolumab + T
tiragolumab + T
2L+ DLBCL
1L PD-L1+ NSCLC
1L esophageal cancer
locally advanced esophageal cancer
stage III unresectable 1L NSCLC
1L non-squamous NSCLC
RG6149
astegolimab (Anti-ST2)
Gazyva
Gazyva
RG7159
Gazyva
Gazyva
Xofluza
RG6152
crovalimab*
RG6107
crovalimab
PNH
aHUS
Xofluza
Ocrevus higher dose
RG1594
RG6114
inavolisib (mPI3K alpha inh)
1L HR+ MBC
Ocrevus SC
giredestrant (SERD)
1L ER+/HER2-mBC
RG3625
TNKase
RMS & PPMS
RMS & PPMS
stroke
lupus nephritis
membranous nephropathy
systemic lupus erythematosus
pediatric nephrotic syndrome
influenza, pediatric (0-1 year)
influenza direct transmission
1Filed in EU
2Approved in US, filed in EU
Registration US & EU (1 NME + 3 Als)
food allergy
COPD
RG6026
RG7446
Columvi (glofitamab)
Tecentriq SC
RG6413+
Ronapreve¹
RG6412
RG7916
Evrysdi²
Roche
3L+ DLBCL
all approved indications
SARS-COV-2 hospitalized
SMA pediatric <2months
RG6171
giredestrant (SERD)
RG6330
giredestrant (SERD) + Phesgo
divarasib (KRAS G12C)
Tecentriq + platinum chemo
Tecentriq
T± chemo
ER+ BC adj
1L ER+/HER2+ BC
2L NSCLC
Enspryng
myasthenia gravis
RG6168
Enspryng
MOG-AD
Enspryng
autoimmune encephalitis
T=Tecentriq
PDS-Port Delivery System with ranibizumab
*First filed in China in Q3 2022
NSCLC periadj
NMIBC, high-risk
RG6356
delandistrogene moxeparvovec (SRP-9001) DMD
fenebrutinib
RMS
RG7845
SCCHN adj
fenebrutinib
PPMS
RG6179
anti-IL-6
UME
RG7446
T + capecitabine or carbo/gem
T + Avastin
1L TNBC
HCC adj
Susvimo (PDS)
DME
RG6321
Susvimo (PDS)
DR
Tecentriq
ctDNA+ high-risk MIBC
Susvimo (PDS)
WAMD, 36-week
T+lurbinectedin
Venclexta
RG7601
RG7828
RG7853
Lunsumio +
Alecensa
Venclexta + azacitidine
Lunsumio + lenalidomide
Polivy
1L maintenance SCLC
r/r MM t(11:14)
1L MDS
2L+ FL
RG7716
Vabysmo (faricimab)
Vabysmo (faricimab)
BRVO
CRVO
2L+ DLBCL
ALK+ NSCLC adj
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other
Status as of April 26, 2023
54View entire presentation